UroGen Pharma edges higher to $27.07 ahead of Goldman Sachs healthcare chat, UroGen Pharma

Traders Union
All News
Companies
UroGen Pharma up 0.84% today

Highlights

URGN trades below short-term averages but remains above medium- and long-term indicators, supporting an overall bullish trend structure.
Momentum is mixed with several indicators showing oversold conditions and trend strength persisting, while sellers currently dominate near-term action.
Expected price range for the coming week is $25.85 to $29.75, with high probability of upward movement unless support at $24.62 fails.

Short-term weakness amid medium-term strength as price tests key resistance

URGN is trading at $27.07, below the MA-20 ($28.80) but above both the MA-50 ($24.62) and MA-200 ($21.61), indicating short-term downward pressure yet maintaining a medium- and long-term bullish structure. The Ichimoku Kijun level on D1 is $27.53, positioned above the current price and signaling immediate resistance; near-term support is at the MA-50 ($24.62), with key support at the MA-200 ($21.61), while resistance is found at the Ichimoku Kijun ($27.53) and next at the MA-20 ($28.80).

Mixed momentum as oversold signals counter persistent trend strength

Momentum signals are mixed: MACD on D1 remains strong buy, and ADX on D1 shows solid trend strength, but both RSI and CCI on D1 indicate oversold conditions, with Stoch RSI confirming a deep oversold state. The BBP on D1 also signals sellers dominate the current momentum. Despite this, Awesome Oscillator is neutral and does not confirm a strong trend direction. URGN has risen $0.22 (0.80%) over the past week, trading up from last week's close of $26.85. The current price sits in the lower part of this week’s $26.23-$29.00 range, with weekly volatility standing at 10.56%. Market tone suggests a steady decline from the weekly high, reflecting the recent loss of upside momentum.

High probability of upward move as weekly indicators favor bulls

For the coming week, a normalized forecast range is $25.85–$29.75, reflecting the typical weekly volatility of URGN and keeping the price comfortably above the 52-week low of $6.73 but below the 52-week high of $32.37. Based on weekly indicator signals—RSI W1 (Buy), ADX W1 (Buy), MACD W1 (Buy), and MA-50 W1 (Buy)—the probability of an upward movement remains very high (more than 80%), making a decline much less likely. The baseline scenario envisions price consolidation between support and resistance. A bullish scenario could see a breakout above $27.53, potentially testing resistance near $28.80. A bearish scenario would materialize if support near $24.62 is breached, exposing the price to further downside toward $21.61.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Previously it was reported that UroGen Pharma appointed Mark, a leading urothelial cancer expert, to strengthen its research and development in urologic oncology. Investors should monitor for further clinical developments or partnership announcements, as these could serve as catalysts for the company's next move.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.